Pembrolizumab,Vibostolimab,Favezelimab
merck
['mibc', 'pembro', 'key,note,45', 'key,note,57', 'nmibc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'bladder', 'mbc']
keynote-057 trial: high-risk nimbc unresponsive to bcg -dfs @ 36 months 35%
-mpfs 44.5 months
-os nr
-pembrolizumab might be an option who declines or are unfit for rc
#gu23 #medtwitter #bladdercancer 
On the road!
Pursuing to improve global health through sharing knowledge, cancer prevention, and care.  
Medical oncologist @AnkaraUni